GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.
RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.
Green tea extract combined with red light therapy is being considered for hair growth on the scalp. Traditional treatments like finasteride, dutasteride, and minoxidil are also mentioned.
Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.
A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.
The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.
NAD⁺ precursors and EGCG may increase hair density, but users report mixed results with no significant hair gains. Some users suggest combining these with finasteride or dutasteride for better results.
Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.
The user experienced noticeable hair regrowth using topical minoxidil and a dermaroller within a month. They are advised to consider DHT inhibition for lasting results.
Whether topical caffeine can be as effective for hair growth as minoxidil and finasteride, with various replies discussing the efficacy of these treatments and criticism of Dr. Huberman's research methods.
The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.
A 21-year-old male with advanced hair loss (NW7) started using finasteride and minoxidil 10 months ago but hasn't seen much progress. He is pre-diabetic with stage 1 hypertension and is seeking insights on whether treating these conditions could improve hair regrowth.
Using retinol with minoxidil may not be as effective as tretinoin, but retinaldehyde or adapalene could be alternatives. A micro-roller with minoxidil is suggested for better results.
A 42-year-old user shares progress on hair loss treatment using finasteride, topical minoxidil, and dermarolling. They seek advice on obtaining Minoxidil pills in Europe.
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.
Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.
The experiences of users who have used RU58841 to treat hair loss, including both positive and negative effects. Some side effects reported include chest pain, joint pain in the hands, tinnitus, and increased heartbeat.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.
RU58841, oral and topical minoxidil, finasteride, and ketoconazole shampoo led to significant hair regrowth, though some suspect a hair transplant. Concerns about RU58841's side effects, like anxiety and heart issues, were discussed.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.